FDA's Transparency Roadmap: What It Means for Clinical Trial Disclosure

By James Greene

Key Takeaways

CSRs are going public in the US. The FDA plans to publish redacted Clinical Study Reports for approved applications, align with EMA transparency practices where feasible, and pilot clinical dataset disclosure.
Registry compliance is being enforced. The FDA is pressing sponsors to post ClinicalTrials.gov results and is encouraging disclosure of INDs at filing.
Public statements will be checked against the record. Published CRLs and the new FDA–SEC information-sharing agreement make selective messaging about regulatory outcomes risky.
Inspections become more visible. Redacted Form 483s and inspection reports will be published proactively.
This is a global shift, not just a US one. As the FDA moves toward EMA practice, the same CSR may be published by several regulators. Redaction and anonymization decisions need to be consistent worldwide.
What to do now: set one redaction and anonymization standard across regulators, audit registry compliance, and align disclosure, regulatory, and communications teams before FY27 guidance arrives.

The US Food & Drug Administration (FDA) has put public release of Clinical Study Reports on its agenda. For US sponsors, clinical document disclosure is moving from a European obligation to a global one.

On October 2, 2026, the FDA published its Transparency Roadmap. It reviews what the agency delivered in FY26 and sets its FY27 priorities. Most headlines will focus on Complete Response Letters and the new FDA–SEC agreement. For clinical disclosure, regulatory, and medical writing teams, the more important change is further down the page.

The FDA says it will publish redacted CSRs for approved applications, align with EMA data transparency practices where feasible, and pilot expanded clinical dataset transparency. Sponsors that have worked through EMA Policy 0070, Health Canada PRCI, and EU CTR will recognize what follows. Sponsors that have not begun, should start planning now. And, because the FDA is aligning with Europe rather than creating a separate system, global consistency in disclosure has become essential.

What the roadmap covers

The roadmap has five areas, and each one changes what becomes public about a sponsor’s product. The FDA presents transparency as a driver of innovation as well as good government: a regulator that explains its reasoning is easier for sponsors to work with and easier for investors and patients to trust.

Area	What changes	Who should pay attention
Complete Response Letters	Continued publication of CRLs, plus rulemaking to disclose the fact that major applications have been submitted	Regulatory affairs, investor relations, communications
Investigational and lifecycle disclosure	IND disclosure at filing, ClinicalTrials.gov enforcement, CSR publication, dataset pilots, FDA–SEC MOU	Clinical disclosure, medical writing, legal
New approach methodologies and biomarkers	Public database of NAM use cases, RWE reporting, Biomarker Qualification Program	Nonclinical, translational, RWE teams
Patient-centered labeling	New one-page Patient Medication Information format	Labeling, regulatory
Compliance and inspections	Proactive release of redacted Form 483s and inspection reports; DTC advertising enforcement	Quality, clinical operations, promotional review

The FDA balances all of this against a long-standing limit. Disclosure must still protect trade secrets, confidential commercial information (CCI), and personal health information submitted in regulatory filings. That limit is where the operational work for sponsors sits.

The headline for disclosure teams: CSRs go public

The FDA plans to increase post-approval disclosure of scientific data so outside researchers can review the evidence behind its decisions. The roadmap lists four commitments:

Publish Clinical Study Reports for approved applications, with confidential commercial and trade secret information redacted
Align with EMA data transparency practices where feasible
Pilot expanded transparency for clinical datasets
Increase post-marketing data disclosures

The FDA’s stated reasons are that independent review can improve clinical practice, increase public confidence in regulatory decisions, and help identify safety signals.

Why the EMA reference matters

The phrase “align with EMA data transparency practices” is the most important detail for sponsors. Under EMA Policy 0070 and EU CTR, sponsors propose redactions for commercially confidential information and anonymize personal data in clinical documents before release. Health Canada’s PRCI follows a similar model. Teams that have done this work know that the volume of CSRs, protocols, and statistical analysis plans, with all of their patient-level detail, makes manual redaction slow and inconsistent.

The roadmap does not yet say how the US process will work: who prepares redactions, on what timeline, or to what anonymization standard. Those details will probably come through later guidance or rulemaking. Whatever the mechanics, the same CSR may be released by more than one regulator. A sponsor that has redacted or anonymized a document one way for Europe needs to be ready to defend a consistent approach in the US.

Datasets are next

The dataset pilot points beyond documents. Releasing individual participant data raises more complex re-identification risks than releasing a redacted report, particularly for rare diseases, small trials, and imaging data. Quantitative risk assessment, not just masking, becomes the standard sponsors will need to meet.

Why this matters beyond the US

The roadmap’s commitment to align with EMA data transparency practices where feasible means US disclosure will become part of a global system rather than a separate set of rules. Most late-stage programs are multinational, so one study’s documents can be published by the EMA under Policy 0070 and EU CTR, by Health Canada under PRCI, and now potentially by the FDA.

This creates a consistency problem. If the same CSR is redacted or anonymized differently for each regulator, anyone who compares the public versions can see what one version hid and another left visible. Information that is safe in one release can enable re-identification when combined with another. Commercially confidential information protected in Europe could be exposed in a US release, or the reverse. A program’s disclosure is only as strong as its least careful release.

The FDA’s choices also travel. The roadmap notes that foreign regulators routinely ask for FDA inspection records when making their own market access decisions, and it describes FDA’s global standing as tied to the credibility of open science. As the largest market moves toward document and dataset publication, other regulators are likely to look at its approach, and global sponsors will be measured against the highest standard any of them applies.

Registries raise the same issue. Multinational trials typically report to ClinicalTrials.gov, CTIS, and other registries. With the FDA enforcing results reporting, discrepancies between registries are more likely to be noticed.

The conclusion for sponsors is to build one global disclosure standard rather than separate regional processes: a single approach to confidential information, a single anonymization method with documented risk thresholds, and registry records that match across jurisdictions.

Registry compliance is under a spotlight

The FDA says it is working to improve sponsor and researcher compliance with ClinicalTrials.gov reporting requirements, and links to its recent reminder to more than 2,200 sponsors and researchers to post trial results.

The FDA’s argument is significant. It says noncompliance leaves gaps in the public record and creates publication bias: successes are overrepresented, failures are underrepresented, and the public sees a distorted picture of product safety and efficacy. That argument treats missing results as a scientific integrity problem, not just a filing error.

The roadmap also encourages sponsors to disclose an IND when they file it. The FDA notes that about 96% of novel drug and biologic filings are already disclosed by the company or by third parties, and argues that early disclosure helps trial enrollment and collaboration and reduces misinformation.

For disclosure teams, three questions now matter more:

Are registrations complete and current across ClinicalTrials.gov, CTIS, and other registries the program uses?
Are results posted within required timelines, including for terminated and unsuccessful studies?
Do registry entries, publications, and public statements describe each trial consistently?

CRLs and the FDA–SEC agreement: public statements must match the record

The FDA is now publishing Complete Response Letters, so a sponsor’s description of a non-approval can be checked against the letter itself. The program started in 2025 with more than 200 CRLs for applications submitted from 2020 to 2024. The FDA cites a 2015 internal analysis that found sponsors left out 85% of its safety and efficacy concerns when they announced non-approvals publicly.

The roadmap describes disclosed CRLs as a growing public record of the FDA’s regulatory reasoning. Sponsors can use them to see which evidence gaps have caused problems for others and to design better development programs. The FDA also plans rulemaking to make public the fact that major applications (NDAs, BLAs, ANDAs and related applications) have been submitted.

In August 2026, the FDA and SEC signed a Memorandum of Understanding to share nonpublic information. The FDA can share information about regulated products and companies, and the SEC can use it in reviewing filings and in enforcement. The FDA says this means companies cannot selectively communicate regulatory developments to markets.

The practical result is that regulatory documents, registry records, press releases, and investor disclosures now form one record that can be compared side by side. Inconsistencies are easier to find, and they now carry securities-law risk as well as reputational risk.

Other areas worth tracking

Inspections. The FDA will proactively publish redacted Form 483s and more establishment inspection reports. It says the public has long asked for this, especially in bioresearch monitoring, which covers clinical investigator and sponsor inspections. Foreign regulators also routinely ask for these records when making their own market access decisions.

New approach methodologies and real-world evidence. In September 2026, the FDA launched a public NAMs Database of Use Case Examples with 25 examples drawn from existing review materials. It continues to publish annual aggregate reports on RWE submissions to CDER and CBER. In both cases, publishing how evidence was used gives the rest of the industry a reference point.

Patient-centered labeling. A planned final rule will create Patient Medication Information, a standardized one-page Medication Guide for outpatient prescription products, written for readers with low health literacy. This matches the plain-language summary requirements sponsors already meet under EU CTR.

Advertising. The FDA’s enforcement against misleading direct-to-consumer advertising, which began in September 2025, remains a priority, with new guidance on modern media under consideration.

What sponsors should do now

The FDA has not yet set out the procedures for US CSR publication, but sponsors don’t need to wait for them to prepare. These steps will be useful whatever the final rules say:

Inventory your exposure. List approved and pending applications whose CSRs could be published, and mark which ones have already been released under EMA Policy 0070, EU CTR, or Health Canada PRCI.
Set one redaction and anonymization standard. Write down how your organization identifies confidential commercial information and anonymizes personal data, and apply it the same way across regulators. If the FDA moves toward EMA practice, documents already prepared for Europe give you a starting point.
Measure re-identification risk. Use quantitative risk assessment, especially for small populations, rare diseases, and any dataset or imaging data that may be included in the dataset pilot.
Write for disclosure from the start. Medical writing that keeps personal data and confidential details out of narrative text where possible reduces redaction work later.
Audit registry compliance. Close gaps in ClinicalTrials.gov registration and results reporting before the FDA does it for you, and include terminated and negative trials.
Connect disclosure, regulatory, and communications teams. With CRLs public and the FDA–SEC agreement in effect, press releases and investor disclosures should be checked against the regulatory record before they go out.
Watch for guidance and rulemaking. Expect FY27 guidance on CSR publication mechanics, dataset pilots, and application disclosure, and budget for it.

How TrialAssure helps

TrialAssure was built for the disclosure work this roadmap describes, and we support sponsors at every stage:

ANONYMIZE anonymizes documents, data, and images for regulatory disclosure. It gives sponsors one consistent, defensible approach to CSRs, datasets, and imaging, whether the document is going to the EMA, Health Canada, or the FDA.
REGISTRY manages clinical trial registration and results disclosure, so registrations stay complete and results are posted on time across registries.
LINK AI supports AI-assisted medical writing, helping teams produce clinical documents with later public release in mind.

The FDA’s message is that clinical evidence should be public by default, with confidential and personal information protected. Sponsors that make that process repeatable will meet the requirements more easily and will be better placed to show their trial results accurately.

To assess your readiness for US CSR publication, contact the TrialAssure team.

FDA’s Transparency Roadmap: What It Means for Clinical Trial Disclosure